Repurposing antimicrobial agents for neuroprotection: Mechanisms, clinical potential, and challenges Authors: Mohammad Amin Manavi, Mohammadreza Salehi, Razieh Mohammad Jafari, Ramin Goudarzi, Saman Khosravi, Ahmad Reza Dehpour Published: 2026 ABSTRACT AbstractAntimicrobial agents, originally developed for infectious diseases, have become attractive candidates for repurposing in neurodegenerative and neuroinflammatory diseases owing to their anti‐inflammatory, antioxidant, immunomodulatory, and neuroprotective activities. In this review, we critically examine the therapeutic potential of selected antimicrobial classes, including tetracyclines (e.g., minocycline), macrolides (e.g., azithromycin), antimalarial agents (e.g., chloroquine/hydroxychloroquine), sulfones (e.g., dapsone), and antiparasitic agents (e.g., ivermectin), in non‐infectious neurological diseases. We performed a narrative review of pre‐clinical and clinical studies to investigate the effects of these agents on the main neuropathological mechanisms, such as neuroinflammation, oxidative stress, mitochondrial dysfunction, impaired autophagy, and gut–brain axis dysregulation. The available evidence suggests that many of the antimicrobial agents have beneficial effects in a number of neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, stroke, and traumatic brain injury. These agents have been shown to modulate microglia activation, to inhibit production of pro‐inflammatory cytokines, and to alter intracellular signaling pathways, including nuclear factor kappa‐light‐chain‐enhancer of activated B cells. Furthermore, by reshaping the gut microbiota, antimicrobials modulate immune signaling, alter neurotransmitter levels, and compromise blood–brain barrier integrity—thereby positioning the gut–brain axis as central to their mechanism of action. Repurposing antimicrobial agents is a pragmatic and novel approach to treat complex neurological disorders with available approved drugs. Despite the encouraging evidence, we must carefully manage challenges such as antimicrobial resistance, off‐target effects, and regulatory considerations. Further well‐designed clinical trials are essential to validate their long‐term safety and efficacy in neurodegenerative and neuroinflammatory diseases.Keywords: anti‐bacterial agents, brain‐gut axis, drug repositioning, neurodegenerative diseases, neuroinflammatory diseases, oxidative stress INTRODUCTION The potential of antimicrobial agents extends far beyond their traditional use in combating infectious diseases. In recent years, growing evidence has highlighted their significant anti‐inflammatory, immunomodulatory, and neuroprotective properties, suggesting a promising role for these drugs in treating non‐infectious diseases. 1 This paradigm shift—known as drug repurposing—offers a cost‐effective and time‐efficient strategy. It addresses unmet medical needs by leveraging the known pharmacokinetics, safety profiles, and therapeutic mechanisms of well‐characterized drugs. 2 Neurological disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), epilepsy, and stroke, are among the most challenging medical conditions. They are characterized by inflammation, oxidative stress, mitochondrial dysfunction, and abnormal autophagy. 3 Interestingly, antimicrobial agents such as minocycline has demonstrated the ability to modulate these pathological mechanisms in various experimental settings. 4 The mechanisms underlying these effects are diverse; Tetracyclines attenuate neuroinflammation by inhibiting microglial activation and cytokine production. 5 Macrolides exhibit immunomodulatory effects that reduce tissue damage in inflammatory conditions. 6 Chloroquine and hydroxychloroquine regulate autophagy and suppress oxidative stress, while sulfones like dapsone modulate apoptotic and inflammatory pathways. Furthermore, antiparasitic agents such as ivermectin and niclosamide show promise in some neurological conditions. They target unique signaling pathways involving gamma‐aminobutyric acid (GABA) receptors as well as mitochondrial integrity. 7 This review will examine the current landscape of antimicrobial agents repurposing, focusing on their neuroprotective potential. By critically evaluating preclinical and clinical evidence, we aim to highlight their unconventional therapeutic applications, underlying mechanisms, and the associated challenges. We focus on representative antimicrobial agents from key drug classes. These include tetracycline macrolides, and antimalarials demonstrating well‐documented anti‐inflammatory or neuroprotective effects. Rather than providing an exhaustive list, we emphasize those with the most robust supporting data to offer meaningful insight into their repurposing potential. Through this review, we aim to uncover how drug repurposing expands the therapeutic horizon of antimicrobial agents and catalyzes advancements in pharmacology, offering new hope for patients suffering from complex, debilitating disorders. TETRACYCLINES (MINOCYCLINE AND DOXYCYCLINE) Minocycline, a second‐generation tetracycline, has emerged as a promising neuroprotective agent beyond its antimicrobial role. Its therapeutic potential lies in modulating neuroinflammatory pathways, reducing oxidative stress, preventing apoptosis, and supporting neurogenesis. These mechanisms are particularly relevant to CNS disorders such as Alzheimer's disease (AD), 8 epilepsy, 9 and spinal cord injury (SCI). 4 The therapeutic mechanisms include inhibition of microglial activation and reduction of oxidative stress. They also suppress pro‐inflammatory cytokines, inhibit apoptotic pathways, and modulate neurotrophic factors. Minocycline possesses greater lipophilicity and blood‐brain barrier (BBB) permeability than other tetracyclines, making it an attractive candidate for neurological applications. 10 Minocycline in epilepsy Neuroinflammation in epilepsy is exacerbated by microglial activation, leading to the release of pro‐inflammatory cytokines. Minocycline effectively inhibits these cytokines production, preventing seizure‐induced neuronal loss. 11 However, a recent study found that minocycline reduced neuroinflammation but did not significantly mitigate seizure‐induced autistic‐like behaviors. This contrasts with rapamycin, an mTOR inhibitor. 12 Early studies on kainic acid (KA)‐induced seizures demonstrated minocyclin's ability to protect hippocampal neurons by inhibiting both caspase‐dependent and independent apoptotic pathways. 13 Furthermore, minocycline mitigated microglial priming in juvenile epilepsy models, reducing susceptibility to later seizures. 14 However, its anticonvulsant effects appear selective, showing efficacy in the 6‐Hz seizure model but not in maximal electroshock (MES) or pentylenetetrazol (PTZ) models, with high doses causing toxicity. 9 Another study found that minocycline has dose‐dependent anticonvulsant effects in a rat model of amygdala‐kindled seizures. It reduced seizure duration, stage 4 latency, and seizure duration at the 50 mg/kg dose. 15 In a lithium‐pilocarpine model of temporal lobe epilepsy, minocycline inhibited microglial activation and reduced pro‐inflammatory cytokine production. This prevented status epilepticus (SE)‐induced neuronal loss. It also reduced the frequency, duration, and severity of seizure‐related seizures 6 weeks after treatment. 11 Further study found that a single oral dose of 200 mg minocycline increased cortical inhibition, primarily due to enhanced GABAergic inhibition. This suggests that minocycline could potentially reduce hyperexcitability, a key feature in epilepsy. This finding aligns with animal models of epilepsy, suggesting minocycline as a promising therapeutic option for refractory seizures. 16 Severe hypoxia can cause seizures, reduced ventilation, and worsened ictal state, posing health risks. Brain microglia play a role in both processes. Inhibiting microglial activation, like minocycline, is reported to delay seizures and prevent ictal episodes in mice. 17 Minocycline in spinal cord injury Following SCI, secondary injury is driven by apoptosis, neuroinflammation, and oxidative stress. Minocycline inhibits caspase‐3 activation, reducing lesion size and improving functional recovery in experimental models. 4 , 18 However, a study using a cervical contusion model in rats found no significant improvement in functional outcomes, suggesting limitations in certain injury types or treatment regimens (90 mg/kg for 3 days). 19 To enhance its therapeutic potential, targeted drug delivery systems have been explored. Recent innovations include nanoliposomes modified with primary macrophage membranes loaded with minocycline and dextran sulfate. These nanocarriers bind calcium ions, reducing neuronal apoptosis and improving SCI recovery in vivo. 20 Additionally, a minocycline‐loaded PαLA‐MP nanoparticle system has demonstrated high biocompatibility and significant neuroprotection in SCI models. 20 Interestingly, minocycline also modulates the gut microbiota post‐SCI, which may influence systemic cytokine levels and anxiety‐like behaviors, further underscoring its multifaceted effects. 21 Minocycline in Alzheimer's disease Minocycline exhibits neuroprotective effects in AD models by attenuating neuroinflammation, reducing astrocyte activation, and decreasing cytokine levels. In a tauopathy model, it lowered phosphorylated tau levels and inflammatory markers, suggesting a role in tau pathology modulation. 11 Additionally, in diabetic‐AD models, minocycline reduced β‐amyloid (Aβ) and tau hyperphosphorylation by inhibiting pro‐inflammatory cytokines rather than directly targeting amyloid precursor protein (APP) or BACE1. 22 Another study revealed that minocycline reduces pro‐inflammatory microglial activation induced by oligomeric Aβ. It also enhances the phagocytosis of fibrillar amyloid‐beta. This dual action suggests that minocycline mitigates neuroinflammation while improving amyloid‐beta clearance, offering a potential therapeutic strategy for AD. 23 Minocycline improves memory and modulates neuroinflammation in an AD mouse model, reversing memory impairment, reducing pro‐inflammatory cytokines, normalizing IL‐10 and IL‐4 levels, and reducing elevated BDNF and NGF levels, 24 suggesting that it effectively mitigates both neuroinflammation and neurotrophic factor dysregulation, offering potential therapeutic benefits for AD‐like dementia. Further, minocycline inhibited Cdk5/p25 signaling and reduced matrix metalloproteinase (MMP‐2, MMP‐9) activity, mitigating synaptic deficits in APP/PS1 mice. 25 Additionally, it improved scopolamine‐induced cognitive deficits by modulating cholinergic function (cholinergic receptor M1 (ChRM1) expression), oxidative stress, and neuroinflammation. 26 Minocycline's ability to reduce phosphorylated tau levels via suppression of TLR‐4/NF‐κB/TNF‐α, and COX‐2 signaling further supports its neuroprotective potential in AD‐like conditions, with higher doses (50 mg/kg) exhibiting greater efficacy than lower doses (25 mg/kg). 27 Minocycline in stroke Minocycline has shown remarkable neuroprotection in ischemic stroke models, with beneficial effects such as reducing infarct size, modulating inflammatory cascades, and protecting neurons from glutamate toxicity. It inhibits IL‐1β‐converting enzyme, COX‐2, and poly (ADP‐ribose) polymerase (PARP), thereby preventing excitotoxic damage. 28 In experimental models, low‐dose minocycline (3–10 mg/kg) effectively reduces neurological deficits, while higher doses (45 mg/kg) significantly decrease infarct volume and microglial activation. Some studies suggest sex‐dependent responses to minocycline in stroke, with males showing greater benefit due to PARP inhibition. 28 , 29 However, further research is needed to elucidate these differences. Minocycline in Parkinson's disease Parkinson's disease (PD) is characterized by progressive dopaminergic neuron loss in the substantia nigra, largely driven by neuroinflammation, oxidative stress, and mitochondrial dysfunction. Minocycline has been found to inhibit microglial activation, suppress inducible nitric oxide synthase (iNOS) expression, and reduce 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced dopaminergic neuron loss in animal models of PD. Furthermore, minocycline attenuates p38 MAPK phosphorylation and oxidative stress, both of which contribute to neuronal degeneration. 30 Studies have demonstrated dose‐dependent neuroprotection (30–120 mg/kg) against MPTP toxicity and enhanced dopamine levels and vesicular dopamine uptake. 31 However, given that most PD studies have been conducted in male models, potential sex differences in minocycline's effects remain an open question. Minocycline in multiple sclerosis Multiple sclerosis (MS) is an autoimmune‐mediated demyelinating disease of the central nervous system. Minocycline has been reported to ameliorate experimental autoimmune encephalomyelitis (EAE), a preclinical model of MS, by reducing microglial activation, shifting T‐cell responses towards a Th2 phenotype, and decreasing pro‐inflammatory cytokine production. 32 Minocycline significantly reduces EAE severity (25–50 mg/kg), inhibits neuroinflammation, and prevents oligodendrocyte loss. Notably, it has been shown to enhance the therapeutic efficacy of methylprednisolone (MP) in combination therapy. However, minocycline's long‐term safety and efficacy in MS remain unclear. 33 Minocycline in amyotrophic lateral sclerosis (ALS) Minocycline, a tetracycline antibiotic with anti‐inflammatory and anti‐apoptotic properties, has been evaluated as a neuroprotective agent in ALS treatment, but its clinical outcomes have been mixed. Initial feasibility trials suggested that minocycline could be tolerated at moderate to high doses. In a small double‐blind, placebo‐controlled study (Trial 1), 19 patients received 200 mg/day for 6 months without significant adverse events (AEs). 34 A follow‐up crossover trial involving 23 participants titrated up to 400 mg/day. Results showed a mean tolerated dose of 387 mg/day, with increased gastrointestinal side effects and elevated blood urea nitrogen and liver enzymes. These findings facilitated the development of the dosing strategies for larger trials. A subsequent pilot study evaluated the safety of combining minocycline with riluzole, the only FDA‐approved drug at the time shown to modestly prolong survival in ALS. In this trial, 20 patients with ALS were randomized to receive either riluzole alone or riluzole in combination with 100 mg/day of minocycline for 6 months. The combination was well tolerated with no significant side effects, suggesting that minocycline can be safely co‐administered with riluzole. However, efficacy was not the primary focus of this study, and further trials were deemed necessary. 35 The largest and most definitive study was a multicenter, randomized, placebo‐controlled phase III trial enrolling 412 ALS patients. After a 4‐month lead‐in, patients were randomized to receive either placebo or minocycline (up to 400 mg/day) for 9 months. Contrary to expectations, disease progression—as measured by the ALS Functional Rating Scale‐Revised (ALSFRS‐R)—was significantly faster in the minocycline group compared to placebo (−1.30 vs. −1.04 units/month; p = 0.005). Non‐significant trends toward faster decline in forced vital capacity and manual muscle testing scores, as well as higher mortality rates, were also observed in the minocycline arm. Importantly, although adverse events were more frequent, particularly gastrointestinal and neurological ones, these did not fully account for the accelerated functional decline. The authors concluded that minocycline may exert deleterious effects in ALS, a finding that has broad implications for the use of minocycline in other neurodegenerative diseases. 36 Recognizing the multifactorial pathophysiology of ALS, a phase II selection trial tested two drug combinations: minocycline (100 mg) with creatine (10 g) versus celecoxib (400 mg) with creatine (10 g), each administered twice daily for 6 months. After the first cohort of 60 patients, ALSFRS‐R decline was slightly greater in the minocycline‐creatine group (6.47) than in the celecoxib‐creatine group (5.27) and historical controls (5.82). Although the difference between the two combinations exceeded the predefined stopping threshold, the futility analysis did not reject the null hypothesis of superiority for either combination. 37 Together, while minocycline's anti‐inflammatory and anti‐apoptotic mechanisms offered theoretical promise, rigorous clinical trials have demonstrated that it may worsen disease progression in ALS. Although safe in combination with riluzole and tolerable in early trials, minocycline failed to show benefit—and even suggested harm—in large‐scale studies. These findings underscore the importance of translational rigor and cautious optimism when repurposing drugs with favorable preclinical profiles. Future ALS therapies may benefit more from targeted combination approaches than from single‐agent interventions like minocycline. Minocycline in depression Minocycline has demonstrated antidepressant‐like effects in preclinical models of depression, particularly those involving neuroinflammation and oxidative stress. It significantly reduces depression‐like behaviors, suppresses IL‐1β and TNF‐α, and inhibits microglial activation. 38 In chronically stressed male mice, minocycline (22.5–45 mg/kg) downregulates quinolinic acid pathway enzymes (IDO‐1, KMO, 3‐HAO), which are implicated in neurotoxicity. Additionally, it inhibits ERK1/2 activation and modulates neuroinflammatory pathways, further supporting its role in depression treatment. 39 However, human trials assessing minocycline's antidepressant efficacy remain limited (Table 1). TABLE 1Neuroprotective effects of minocycline in preclinical models of neurological and neuropsychiatric disorders.DiseaseDose and route of administrationAnimal modelMechanisms and outcomes of treatmentLimitationsRef.Spinal Cord Injury90 mg/kg (1 h post‐SCI), then 45 mg/kg q12 h for 3 daysAdult male Sprague Dawley rats proNGF expression ↓ p38MAPK ↓ p75NTR expression and RhoA activation ↓ apoptosis of oligodendrocytes ↓ Myelin and axonal loss ↓ On−ly male rats evaluated.[40]50 mg/kg/day p.o. for one weekAdult female Lewis rats, 200 g No effect on lesion size Affective but not motor recovery ↑ inflammatory cytokines/chemokines in the plasma ↓ Only female rats evaluated.[21]Stroke45 mg/kg i.p. twice a day for the first day; 22.5 mg/kg for the subsequent 2 daysMale Sprague–Dawley rats, 250 g IL‐1β‐converting enzyme ↓ COX‐2 expression and prostaglandin E2 production ↓ Glutamate toxicity ↓ Only male rats evaluated.[41]3‐10 mg/kg, i.v.Male Sprague‐Dawley rats, 300 gNeurological deficits ↓Only male rats evaluated. Without molecular assessment.[29]45 mg/kg i.p. twice a daywild‐type 57/B6 male and female mice Infarct volume ↓ poly (ADP‐ribose) polymerase (PARP) ↓ loss of PARP‐1 protects males but not females Limited number of molecular tests[28]10, 25, or 50 mg/kg, i.p., daily for 2 weeksMale C57BL/6 mice, 10 weeks brain infarct volume and neuronal injury and reactive gliosis ↓ microglial polarization M1 ↓ and M2 ↑ via STAT1/STAT6 pathway Only male mice evaluated.[42]1 mg/kg, i.v.Male Long‐Evans (LE) rats, 220 g Motor Performance in Horizontal Runway Elevated test and Grip Strength test ↑ HuR, TNF‐α, and HSP70 levels in the peri‐infarct area ↓ Only male rats evaluated.[43]Epilepsy90 mg/kg then 45 mg/kgAdult male ICR mice, 35 g Cytochrome c and apoptosis‐inducing factor (AIF) ↓ Hippocampal cell death ↓ Cleaved caspase‐3 ↓ Only male mice evaluated.[13]20 mg/kgCx3cr1GFP/+ transgenic miceEarly life seizure‐induced microglial cell activation ↓Limited number of molecular tests. Sex did not determine.[14]ED50 of 170 mg/kgAdult male CF no 1 albino mice and SD albino ratsAnticonvulsant Effect in 6 Hz Test but not maximal electrical shockOnly male mice or rats evaluated. Without molecular tests.[9]50 mg/kg, i.p.Adult male Wistar rats, 8 weeksamygdala‐kindled seizures ↓Only male rats evaluated. Without molecular tests.[15]45 mg/kg for 2 weeks after SEAdult male SD rats 200 g IL‐1β and TNF‐α in the hippocampal CA1 and the adjacent cortex ↓ Microglial activation without interfering with reactive astrocytes ↓ Neuronal loss ↓ Only male rats evaluated.[11]100 mg/10 mL minocycline was administered intrathecally17–19‐week‐old adult non‐epileptic male Wistar ratsp38 MAPK and Microglia activity ↓Only male rats evaluated.[44]Parkinson'sdisease60, 90, or 120 mg/kgmale C57BL/6 mice MPTP neurotoxicity ↓ MPTP/MPP+‐induced glial iNOS expression ↓ NO‐induced phosphorylation of p38 MAPK in CGN ↓ Only male mice evaluated.[30]45 mg/kg of minocycline beginning 24 h after lesioningMale Fisher 344 rats Tyrosine hydroxylase‐positive cell loss ↓ Loss of TH‐immunoreactive cells in 6‐OHDA‐lesioned nigras ↓ TH‐immunoreactive cell size and fiber density in lesioned nigras ↑ Only male rats included.[31]30 mg/kg once daily for 2 weeksMale Swiss albino mice Mitochondrial function ↑ Did not change microglia activation Only male mice included.[45]Alzheimer's disease50 mg/kg/day for 2 daysAPP1PS1 doubletransgenic female mice No effect on BM‐derived cell Proliferation/viability in vitro or Phagocytic Activity ex vivo No effect on LPS‐triggered reduction of Hippocampal Aβ burden Female mice only obtained.[46]50 mg/kg/day for 1 monthMice carry the human APP transgene delaying the development of AD Neuroinflammation in young, pre‐plaque Tg mice ↓ β‐site APP cleaving enzyme 1 (BACE‐1) ↓ iNOS ↓ Only one dose evaluated.[8]50 mg/kg/day for 1 weekmale APP/PS1 transgenic mice Learning and memory ↑ MMP‐2 and MMP‐9 ↓ Total tau and hyperphosphorylated tau ↓ Activity of β‐ and γ‐secretases ↓ Activation of Cdk5/p25 Signaling ↓ Male mice only obtained.[25]Multiple sclerosis25 mg/kg/day for 1 weekC57/BL6 mice EAE severity ↓ Neuropathology of EAE ↓ Th2 shift ↑ Sex did not determine.[32]25 mg/kg daily, i.p.female C57 BL/6 mice EAE severity when combined with MP ↓ Neuropathology of EAE ↓ IFN‐γ and IL‐4 modulation ↑ Female mice only obtained.[33] Note: All studies were conducted in animal models; no clinical data are included. ↑ increase; ↓ decrease.Abbreviations: BM, bone marrow; DA, dopamine; DOPAC, 3,4‐dihydroxyphenylacetic acid; EAE, experimental autoimmune encephalomyelitis; GFAP, glial fibrillary acidic protein; HMGB1, high mobility group box 1; i.p., intraperitoneal; i.v., intravenous; MMP, matrix metalloproteinase; MP, methylprednisolone; NSCs, neural stem cells; PARP, poly (ADP‐ribose) polymerase; po, per os; SCI, spinal cord injury; SD, Sprague–Dawley; SE, status epilepticus; TH, tyrosine hydroxylase; TLE, temporal lobe epilepsy. Neuroprotective effects of minocycline in preclinical models of neurological and neuropsychiatric disorders. proNGF expression ↓ p38MAPK ↓ p75NTR expression and RhoA activation ↓ apoptosis of oligodendrocytes ↓ Myelin and axonal loss ↓ No effect on lesion size Affective but not motor recovery ↑ inflammatory cytokines/chemokines in the plasma ↓ IL‐1β‐converting enzyme ↓ COX‐2 expression and prostaglandin E2 production ↓ Glutamate toxicity ↓ Infarct volume ↓ poly (ADP‐ribose) polymerase (PARP) ↓ loss of PARP‐1 protects males but not females brain infarct volume and neuronal injury and reactive gliosis ↓ microglial polarization M1 ↓ and M2 ↑ via STAT1/STAT6 pathway Motor Performance in Horizontal Runway Elevated test and Grip Strength test ↑ HuR, TNF‐α, and HSP70 levels in the peri‐infarct area ↓ Cytochrome c and apoptosis‐inducing factor (AIF) ↓ Hippocampal cell death ↓ Cleaved caspase‐3 ↓ IL‐1β and TNF‐α in the hippocampal CA1 and the adjacent cortex ↓ Microglial activation without interfering with reactive astrocytes ↓ Neuronal loss ↓ MPTP neurotoxicity ↓ MPTP/MPP+‐induced glial iNOS expression ↓ NO‐induced phosphorylation of p38 MAPK in CGN ↓ Tyrosine hydroxylase‐positive cell loss ↓ Loss of TH‐immunoreactive cells in 6‐OHDA‐lesioned nigras ↓ TH‐immunoreactive cell size and fiber density in lesioned nigras ↑ Mitochondrial function ↑ Did not change microglia activation No effect on BM‐derived cell Proliferation/viability in vitro or Phagocytic Activity ex vivo No effect on LPS‐triggered reduction of Hippocampal Aβ burden delaying the development of AD Neuroinflammation in young, pre‐plaque Tg mice ↓ β‐site APP cleaving enzyme 1 (BACE‐1) ↓ iNOS ↓ Learning and memory ↑ MMP‐2 and MMP‐9 ↓ Total tau and hyperphosphorylated tau ↓ Activity of β‐ and γ‐secretases ↓ Activation of Cdk5/p25 Signaling ↓ EAE severity ↓ Neuropathology of EAE ↓ Th2 shift ↑ EAE severity when combined with MP ↓ Neuropathology of EAE ↓ IFN‐γ and IL‐4 modulation ↑ Note: All studies were conducted in animal models; no clinical data are included. ↑ increase; ↓ decrease. Abbreviations: BM, bone marrow; DA, dopamine; DOPAC, 3,4‐dihydroxyphenylacetic acid; EAE, experimental autoimmune encephalomyelitis; GFAP, glial fibrillary acidic protein; HMGB1, high mobility group box 1; i.p., intraperitoneal; i.v., intravenous; MMP, matrix metalloproteinase; MP, methylprednisolone; NSCs, neural stem cells; PARP, poly (ADP‐ribose) polymerase; po, per os; SCI, spinal cord injury; SD, Sprague–Dawley; SE, status epilepticus; TH, tyrosine hydroxylase; TLE, temporal lobe epilepsy. Bipolar disorder may involve immune‐inflammatory mechanisms contributing to its pathophysiology, particularly during manic episodes. Beyond minocycline, other tetracyclines such as doxycycline have also shown potential. Further study evaluated the effects of doxycycline in a d‐amphetamine‐induced mania model in mice. Doxycycline (25 or 50 mg/kg) administered alone or with lithium from Days 8 to 14 reversed hyperlocomotion, cognitive deficits, and neuroinflammatory markers such as TNF‐α, MPO, and hippocampal Iba1. Doxycycline also reduced oxidative stress markers, including lipid peroxidation and nitrite, while enhancing phosphorylated GSK3β (Ser9) when combined with lithium. 5 These findings suggest doxycycline as a promising adjunctive treatment for bipolar disorder, particularly for addressing cognitive impairments and neuroimmune changes, providing a rationale for future clinical trials. Limitations and future directions Despite the promising neuroprotective effects of tetracyclines, several challenges remain: (1) Limited sex‐based studies: Most preclinical studies have been conducted in male animals, leaving sex‐specific responses largely unexplored. (2) Optimal dosing strategies: The therapeutic window, long‐term safety, and dose‐dependent effects require further clarification. (3) Translation to human trials: While preclinical data are compelling, clinical trials assessing the efficacy of tetracyclines in neurological disorders remain scarce. Future research should focus on: (1) Expanding clinical trials to validate the neuroprotective potential of minocycline and doxycycline. (2) Investigating sex‐specific responses to improve translational relevance. (3) Combining tetracyclines with other neuroprotective agents to enhance therapeutic efficacy. MACROLIDE‐DERIVED AGENTS (AZITHROMYCIN, TACROLIMUS, AND RAPAMYCIN) Macrolides have garnered increasing interest in recent years for their neuroprotective effects in the CNS. Azithromycin is a widely used macrolide antibiotic that exhibits anti‐inflammatory and immunomodulatory properties beyond its antimicrobial effects. Research has indicated that azithromycin can cross the BBB, allowing it to exert direct effects on neuronal and glial cells in the CNS. Azithromycin has been shown to inhibit the production of pro‐inflammatory cytokines such as TNF‐α and IL‐6 in activated microglia and astrocytes. 47 Azithromycin in ischemic brain injury Azithromycin demonstrated neuroprotective effects in a neonatal rodent model of hypoxic‐ischemic brain injury by improving sensorimotor function and reducing brain damage. Efficacy was dose‐dependent, with better outcomes observed when treatment was initiated earlier. Multiple injections over 48 h were more effective than a single dose. 48 Similarly, azithromycin showed neuroprotective effects in a model of optic neuropathy induced by optic nerve crush (ONC) in male C57Bl/6 wild type (WT) and female NOD SCID gamma (NSG) mice. Azithromycin treatment reduced retinal ganglion cell (RGC) apoptosis, with greater preservation in WT mice compared to NSG mice. Azithromycin also reduced microglial activation after ONC. Molecular analysis revealed that azithromycin modulated stress‐related and inflammatory markers differently in WT and NSG mice. In WT mice, azithromycin increased the expression of Sod1 and NF‐κB in the optic nerve and decreased Bax and HO‐1 in the retina, while these markers remained stable or decreased in NSG mice. The lack of a significant effect in immunodeficient NSG mice suggests azithromycin's neuroprotection is mediated through immunomodulation. These results highlight azithromycin's potential for repurposing to protect RGCs in acute optic neuropathies. 49 Further study examined the neuroprotective effects of azithromycin and sildenafil on RGC survival in a glaucoma model induced by microbead injection in 50 WT and 30 transgenic toll‐like receptor 4 (TLR4) knockout mice. Azithromycin reduced the BAX/BCL2 ratio, TGF‐β, and TNF‐α levels in the optic nerve and CD45 expression in the retina and provided neuroprotection in both WT and knockout mice with microbead‐induced glaucoma through different mechanisms, without affecting IOP. 50 Furthermore, another study investigated the neuroprotective effects of azithromycin in female C57BL6J mice subjected to LPS administration. Azithromycin reversed the increase in immobility time in the Porsolt test (forced swim test), as a behavioral despair test, and reduced pro‐inflammatory cytokine levels in the hippocampus. It also mitigated adult hippocampal neurogenesis impairments and enhanced the synaptic integration of adult‐born neurons, while functionally remodeling the gut microbiome. 51 Azithromycin in spinal cord injury In terms of SCI, several studies have evaluated the possible protective effects of azithromycin. The first study shows that azithromycin significantly improved SCI by promoting anti‐inflammatory macrophage phenotypes and reducing pro‐inflammatory ones. This led to improved tissue preservation and locomotor function recovery through increased M2 and decreased M1 macrophage activation. 52 Azithromycin effectively polarizes macrophages toward a reparative M2 phenotype following SCI, thereby promoting tissue and functional recovery. Administered starting 30 min post‐SCI and continued for 3 to 7 days, azithromycin treatment led to a dose‐dependent decrease in pro‐inflammatory M1 macrophage gene expression at 3 days post‐injury, increased M2 macrophage gene expression by 7 days post‐injury. 53 These findings underscore azithromycin's immunomodulatory properties and its potential as a therapeutic agent for enhancing recovery in SCI, demonstrating the utility of comprehensive macrophage gene profiling in evaluating such immunomodulatory treatments. 54 When administered 30 min or 3 h post‐injury, azithromycin significantly improved locomotor recovery. This was indicated by an enhanced stepping function compared to vehicle controls. Moreover, starting treatment 30 min after the injury notably reduced lesion pathology. However, delaying treatment until 24 h post‐injury was ineffective. While azithromycin did not significantly alleviate neuropathic pain (mechanical allodynia) or increase neuron survival, 55 these findings bolster the growing body of evidence supporting azithromycin translational potential as a therapeutic option for SCI and other neuroinflammatory conditions, where treatment alternatives are currently limited. Beyond conventional antimicrobial macrolides such as azithromycin, certain macrolide‐derived compounds, including tacrolimus (FK506) and rapamycin (sirolimus), have attracted increasing attention because of their immunomodulatory and neuroprotective properties. Although primarily used as immunosuppressive agents in clinical practice, these compounds are structurally related to macrolide antibiotics and were included in the present review because of their potential therapeutic relevance in neurological disorders. Tacrolimus and epilepsy Tacrolimus, also known as FK‐506, has been extensively used to prevent organ rejection as an immunosuppressive macrolide in transplant recipients. Beyond its immunosuppressive effects, tacrolimus has been recognized for its neuroprotective properties, particularly in neuroinflammatory and neurodegenerative disorders. 56 , 57 Further study utilized X‐ray fluorescence microscopy with synchrotron radiation to conduct topographic and quantitative elemental analyses of rat brain tissue in a pilocarpine‐induced status epilepticus (SE) model, focusing on the neuroprotective effects of tacrolimus. Status epilepticus refers to seizures lasting 5 min or more without recovery between seizures, characterized by continuous clinical and/or electrographic seizure activity. The mass per unit area of various elements—P, S, Cl, K, Ca, Fe, Cu, Zn, Se, Br, and Rb—was assessed in four regions of the hippocampal formation (CA1, CA3, dentate gyrus, and hilus) as well as the parietal cortex. Notable differences in elemental composition were found between treated and untreated epileptic rats. Tacrolimus‐treated rats exhibited higher phosphorus levels in CA1 and CA3 regions. They also showed increased potassium across all brain areas analyzed. Additionally, elevated iron levels were detected in the CA3 and dentate gyrus, while copper and zinc levels were higher in the parietal cortex and CA3, respectively, in the tacrolimus group compared to the untreated epileptic rats. These findings suggest that tacrolimus neuroprotective effects in the epileptic rat brain may involve mechanisms beyond calcineurin inhibition, potentially including the blockade of potassium channels. 58 A study found that tacrolimus significantly enhanced hippocampal neuron survival in rats with SE, decreasing nitric oxide, NOS, and malondialdehyde levels. It also reversed SE‐induced reduction in MMP and prevented mitochondrial expansion. Tacrolimus also modulated apoptotic pathways, suggesting its neuroprotective effects. 59 Further study examined the neuroprotective effects of tacrolimus and cyclosporine A (CsA) against hypoxic damage in rat spinal cord tissue. Following a 1‐h hypoxic exposure, significant decreases in mitochondrial ATP and reduced glutathione (GSH) were observed, alongside marked increases in lipid peroxidation (LPO) levels and myeloperoxidase (MPO) activity. Treatment with tacrolimus (0.1 μM) and CsA (0.1 μM) yielded significant neuroprotective effects, increasing ATP levels by 11.19% and 16.14%, and GSH content by 66.46% and 77.32%, respectively. Additionally, LPO levels decreased by 18.97% and 24.06%, while MPO levels reduced by 42.86% and 18.66% following tacrolimus and CsA treatment. Furthermore, FK‐506 treatment reduced calcium uptake in mitochondria, as indicated by an 11.19% increase in absorbance. TTC staining confirmed increased tissue viability post‐treatment. These findings suggest that FK‐506 and CsA exert significant neuroprotective effects against spinal cord hypoxia, likely through their antioxidant actions. 60 Based on a recent systematic review, these medications could be beneficial in peripheral nerve regeneration. This systematic review examined the effects of the immunosuppressants such as tacrolimus and cyclosporine on peripheral nerve regeneration, analyzing 56 articles published until September 2018, with 22 included in the meta‐analysis. The findings indicate a significant protective effect of tacrolimus on the regeneration of myelinated axons, with a 95% confidence interval (CI) of 0.93–2.39 (p < 0.01), while cyclosporine did not demonstrate a significant effect (95% CI: −0.38–1.18; p = 0.08). Additionally, tacrolimus use was associated with increased myelin thickness (95% CI = 2.00–5.71; p < 0.01). Overall, the use of immunosuppressants, particularly tacrolimus, promoted an increase in the number of myelinated axons, enhanced myelin thickness, improved muscle weight, and facilitated recovery as measured by the sciatic functional index. However, the analysis noted a high level of heterogeneity across studies, indicating variability in results. 61 Neuroprotective effects of rapamycin Rapamycin, another macrolide antibiotic, is primarily known for its role as an immunosuppressant in organ transplantation and as a potential anti‐cancer agent. Recent studies have revealed its neuroprotective properties, particularly in the context of age‐related neurodegenerative diseases. Rapamycin functions as an inhibitor of the mechanistic target of the rapamycin (mTOR) pathway, which regulates cellular growth, metabolism, and autophagy. Inhibition of mTOR has been associated with neuroprotective effects, including enhanced autophagy and clearance of toxic protein aggregates commonly seen in neurodegenerative diseases like AD and PD. 62 A recent study demonstrated the neuroprotective effects of rapamycin in SCI through activation of the Wnt/β‐catenin signaling pathway. In SCI‐induced rats, intraperitoneal administration of rapamycin for 2 days increased the expression of β‐catenin and brain‐derived neurotrophic factor (BDNF) while reducing caspase‐3 levels, a marker of apoptosis. These biochemical changes were accompanied by improved histological outcomes, including reduced motor neuron loss and enhanced tissue morphology at the injury site. Functionally, rapamycin treatment promoted motor recovery, suggesting that its activation of Wnt/β‐catenin signaling supports neuronal survival and neural repair. 63 Recent research assessed rapamycin's neuroprotective effects against cisplatin‐induced peripheral neuropathy (CIPN). Experiments on adult male Balb/c mice using various pain assays showed that rapamycin significantly alleviated nociceptive symptoms associated with cisplatin treatment. It worked by reversing increases in inflammatory mediators like IL‐17A and CD8 + T cells linked to CIPN progression, reducing neuronal apoptosis as indicated by lower caspase‐3 activity, and modulating proteins relevant to cell cycle and apoptosis, such as p21Cip1, p53, and PUMA. These results highlight rapamycin's potential as a therapeutic option for CIPN, necessitating further exploration of its mechanisms and clinical use. 64 Rapamycin in neurodegenerative diseases Numerous studies have been conducted on the effect of rapamycin on neurodegenerative diseases such as AD and PD. For example, one study investigated the neuroprotective effects of the autophagy enhancer rapamycin against rotenone‐induced neurotoxicity, a model mimicking key pathogenic mechanisms of PD. Using rotenone‐exposed SH‐SY5Y neuronal cells, rapamycin treatment significantly reduced apoptosis and ubiquitinated protein accumulation. Silencing Atg5 partially reversed these effects, highlighting the dependence on autophagic pathways. Rapamycin also reduced mitochondrial damage by decreasing cytochrome c release into the cytosol and preserving the mitochondrial marker COX IV, indicating enhanced mitophagy—the selective autophagic clearance of damaged mitochondria. Co‐localization studies revealed lysosomes and mitochondria within autophagy‐associated double‐membrane structures, supporting the hypothesis that rapamycin promotes the turnover of dysfunctional mitochondria. 65 Further study explored the neuroprotective mechanism of rapamycin against cadmium (Cd)‐induced neuronal toxicity, focusing on its interaction with mTOR signaling. Rapamycin significantly prevented Cd‐induced apoptotic cell death in neuronal cells by inhibiting the phosphorylation of Akt, S6K1, and 4E‐BP1, all downstream targets of mTOR. Using mutant mTOR constructs, the study demonstrated that rapamycin's effects depend on its suppression of mTOR kinase activity. Both mTORC1 and mTORC2 complexes were implicated, as silencing raptor, rictor, or both potentiated rapamycin's neuroprotective effects. Further, downregulating S6K1, introducing hypophosphorylated 4E‐BP1, or inhibiting Akt amplified rapamycin's action. These findings suggest that rapamycin prevents Cd‐induced neuronal apoptosis by targeting mTORC1 and mTORC2, positioning it as a potential therapeutic agent against Cd‐induced neurodegenerative disorders. 66 A study investigated the long‐term neuroprotective effects of rapamycin in synucleinopathy using a transgenic mouse model expressing A53T α‐synuclein, which mirrors key features of Parkinson's disease and related disorders. Mice were fed a rapamycin‐enriched diet (2.25 mg/kg body weight/day) for 24 weeks. Behavioral tests revealed significant motor improvements in rapamycin‐treated mice, evidenced by better performance in forepaw stepping, rotarod, and pole tests. Biochemically, rapamycin reduced oxidative damage, as indicated by decreased levels of proteins adducted to the lipid peroxidation product 4‐hydroxynonenal. Although rapamycin did not reduce α‐synuclein content or alter monoamine levels in the midbrain or striatum, it mitigated synaptophysin loss, a presynaptic marker, in affected brain regions. In SH‐SY5Y cells treated with 4‐hydroxynonenal, rapamycin preserved synaptophysin and neurite length, further supporting its protective role. These findings suggest that rapamycin, an FDA‐approved drug, holds promise as a treatment for synucleinopathies by alleviating oxidative damage and synaptic loss. 67 Another study explored the neuroprotective effects of mTOR inhibition via rapamycin against excitotoxicity induced by quinolinic acid (QA) in mice. QA, administered unilaterally in the striatum, caused motor impairment, neuronal cell death, inflammatory cytokine release, and changes in astrocyte density. Pretreatment with rapamycin (0.2, 2, or 20 μM doses) mitigated motor deficits, reduced neuronal degeneration (assessed by Fluoro‐Jade C staining), and suppressed QA‐induced increases in pro‐inflammatory cytokines IL‐1β, IL‐6, and TNF‐α. Additionally, the lowest rapamycin dose enhanced IL‐10 levels, an anti‐inflammatory cytokine, and prevented QA‐induced astrocyte density reduction. In vitro experiments using striatal synaptosomes demonstrated dose‐dependent modulation of glutamate release by rapamycin, with lower concentrations reducing and higher concentrations enhancing glutamate release. These findings highlight the detrimental role of mTOR in excitotoxic neurodegeneration and suggest mTOR inhibition as a potential therapeutic approach for neurodegenerative diseases. 68 Further study demonstrates that rapamycin‐induced activation of autophagy provides neuroprotection in aging‐related brain degeneration in rats by reducing oxidative stress, neuroinflammation, and apoptotic cell death, while preserving markers of cellular rejuvenation and neuronal integrity, such as Na+/K+‐ATPase, Ca2+‐ATPase, and acetylcholinesterase activities. Administering rapamycin (0.5 mg/kg body weight for 28 days) restored homeostasis, suggesting that autophagy plays a pivotal role in mitigating aging‐induced neuronal damage. These findings position rapamycin as a promising intervention to delay brain aging and reduce susceptibility to neurodegenerative disorders. 69 This study investigates the effects of intranasal rapamycin administration in Ts65Dn mice, a model for Down syndrome (DS), aiming to rescue the disrupted mTOR signaling, which is implicated in AD pathology. After 12 weeks of treatment starting at 6 months of age, the mice exhibited improved cognition, as shown by behavioral tests like the radial arm maze and novel object recognition. Intranasal rapamycin treatment restored physiological levels of mTOR signaling, enhanced autophagy and insulin signaling, and reduced APP levels, APP processing, tau hyperphosphorylation, and oxidative stress markers. These results suggest that chronic intranasal rapamycin administration can reduce AD‐like neuropathology and cognitive decline in DS, offering a potential therapeutic approach for mitigating neurodegeneration in individuals with DS. 70 Rapamycin, a well‐known autophagy inducer, has shown neuroprotective effects in PD, but its connection to ferroptosis in this context was not fully understood until recent studies. In this study, rapamycin was administered to two PD models: a mouse model induced by MPTP and a PC12 cell model induced by 1‐methyl‐4‐phenylpyridinium (MPP+). The results demonstrated that rapamycin improved behavioral symptoms, reduced dopamine neuron loss in the substantia nigra pars compacta, and lowered ferroptosis‐related markers such as glutathione peroxidase 4 (GPX4), solute carrier family 7 member 11 (SLC7A11), glutathione (GSH), malondialdehyde (MDA), and reactive oxygen species (ROS). Additionally, rapamycin improved cell viability and decreased ferroptosis in the PD cell model. Importantly, the neuroprotective effects of rapamycin were reversed by a ferroptosis inducer and an autophagy inhibitor (3‐methyladenine), indicating that rapamycin's beneficial effects are likely mediated through the inhibition of ferroptosis via autophagy activation. These findings suggest that targeting ferroptosis and autophagy pathways may provide new therapeutic strategies for treating PD. 71 Recent studies have shown that TAR DNA‐binding protein (TDP‐43), associated with neurodegenerative diseases like ALS and AD, is involved in stroke pathology. Treatment with rapamycin reduced TDP‐43 fractions in the ischemic cortex, restored mitochondrial function, decreased cell apoptosis, reduced infarct size, and improved motor function, suggesting rapamycin may offer neuroprotective benefits for ischemic stroke treatment. 72 A summary of neuroprotective effects of macrolides in preclinical studies is in Table 2. TABLE 2Neuroprotective effects of macrolides (azithromycin, tacrolimus, and rapamycin) in preclinical studies.DiseaseDose and route of administrationAnimal modelMechanisms and outcome of treatmentLimitationsRef.Spinal Cord InjuryAzithromycin: 160 mg/kg, oral gavagemoderate‐severe thoracic contusion in mice (C57BL/6J, 3‐month‐old) M2 and Secondary injury improvement ↑ M1 ↓ Only female mice included.[52, 53]Azithromycin: 160 mg/kg, 30‐min, 3‐h, or 24‐h following injurycontusion SCI in female mice did not reduce neuropathic pain did not increase neuron survival Only one dose selected. Only female mice included.[55]Tacrolimus: 0.25 mg/kg for 3 daysSD rats with T9 laminectomyGAP‐43 immunoreactivity ↑Sex did not determine.[73]Tacrolimus: 0.1 μMMale Wistar rats Mitochondrial improvement ↑ LPO, MPO, and Calcium uptake ↓ Only male rats included. Dose was not mentioned.[60]Rapamycin: 1 mg/kg, i.p. 4 h after injuryFemale C57BL/6 J mice locomotor activity ↑ by inhibiting the mTOR signaling pathway, LC3 and Beclin 1 ↑ p70S6K protein phosphorylation ↓ Only female mice included. Short‐term follow‐up.[74]Rapamycin: 1 mg/kg, i.p. for 3 daysFemale rats with Allen weight drop TNF‐α and IL‐1β levels and apoptotic cells ↓ Neurons survival ↑ Only female rats included.[75]StrokeAzithromycin: 0.15‐150 mg/kgAdult C57Bl/6 male miceM2 phenotype macrophage, as well as arginase activity ↑Only male mice included.[76]Azithromycin: 150 mg/kg, i.p. upon reperfusionC57Bl/6 male PARP‐1 knockout (PARP‐/‐) and wild type (WT) miceIschemic stroke injury protection ↑ independent of PARP activationOnly male mce included.[77]Tacrolimus: 1 mg/kg one min after MCAOMale Lister‐hooded rats Deficits in skilled motor ability ↓ Neural tissue protection ↑ Only male rats included.[78]Tacrolimus: 0.025, 0.05, 0.1, 0.25, 0.5 or 1.0 mg/kg/dayPregnant SD ratIL‐1β in CA3 region and Neuronal Cell Loss ↓Only pregnant rats included[79]Rapamycin: 0.625, 1.25, 2.5 mg/kgC57BL/6J male mice Infarct size ↓ Brain LC3I/II ration improvement ↑ Only male mice included. Limited molecular assessments.[80]Rapamycin: 6 mg/kg before and after MCAOMale SD rats p‐mTOR, p‐S6, and p‐DRP1 ↓ SIRT3 and Nix/BNIP3L ↑ Only male rats included.[81]EpilepsyTacrolimus: 0.5 mg/kg pretreatment 1 h and 24 h beforeMale Wistar rats in Li‐pilocarpine SENO, nNOS, iNOS, MDA ↓Only male rats included.[59]Tacrolimus: 10 mg/kgC57BL6/J male and female mice Pten‐/‐ Deletion effect and intrinsic excitability ↓ Spontaneous GABA Release ↑ Only one dose selected.[82]Tacrolimus: 6 mg/kgYoung adult male mice C57BL/6 spontaneous EPSCs in granule cells ↓ Mossy fiber sprouting ↓ Only male mice included.[83]Parkinson's diseaseRapamycin: 20 mcg/ml i.v. for 1 weekMale C57BL/6 miceTH Expression, a‐synuclein and LC3 ↓Only male mice included.[84]Rapamycin: 0.05, 0.5, and 5 mg/kgFemale SD ratsBcl‐2/Bax ↑Only female rats.[85]Rapamycin: 7.5 mg/kgC57BL/6 male mice Glutamate transporters ↑ IL‐6 and JAK2/STAT3 pathway ↓ Only male mice included.[86]Alzheimer's diseaseRapamycin: 7.5 mg/kgMale SD rats Mitophagy ↑ via PI3K/AKT/mTOR Apoptosis ↓ Only male rats included.[87]Rapamycin: 2.5 mg/kg, single injectionHybrid MiceOxidative stress ↓tau hyperphosphorylation ↓Only one dose evaluated.[70] Note: All studies were conducted in animal models; no clinical data are included. ↑ increase; ↓ decrease.Abbreviations: GAP‐43, growth associated protein 43; GSH, glutathione; i.p., intraperitoneal; i.v., intravenous; LC3, microtubule‐associated protein 1 light chain 3; MCAO, middle cerebral artery occlusion; M1/M2, classically/alternatively activated microglia/macrophages; MDA, malondialdehyde; MPO, myeloperoxidase; SCI, spinal cord injury; SD, Sprague–Dawley; SE, status epilepticus; WT, wild type. Neuroprotective effects of macrolides (azithromycin, tacrolimus, and rapamycin) in preclinical studies. M2 and Secondary injury improvement ↑ M1 ↓ did not reduce neuropathic pain did not increase neuron survival Mitochondrial improvement ↑ LPO, MPO, and Calcium uptake ↓ locomotor activity ↑ by inhibiting the mTOR signaling pathway, LC3 and Beclin 1 ↑ p70S6K protein phosphorylation ↓ TNF‐α and IL‐1β levels and apoptotic cells ↓ Neurons survival ↑ Deficits in skilled motor ability ↓ Neural tissue protection ↑ Infarct size ↓ Brain LC3I/II ration improvement ↑ p‐mTOR, p‐S6, and p‐DRP1 ↓ SIRT3 and Nix/BNIP3L ↑ Pten‐/‐ Deletion effect and intrinsic excitability ↓ Spontaneous GABA Release ↑ spontaneous EPSCs in granule cells ↓ Mossy fiber sprouting ↓ Glutamate transporters ↑ IL‐6 and JAK2/STAT3 pathway ↓ Mitophagy ↑ via PI3K/AKT/mTOR Apoptosis ↓ Note: All studies were conducted in animal models; no clinical data are included. ↑ increase; ↓ decrease. Abbreviations: GAP‐43, growth associated protein 43; GSH, glutathione; i.p., intraperitoneal; i.v., intravenous; LC3, microtubule‐associated protein 1 light chain 3; MCAO, middle cerebral artery occlusion; M1/M2, classically/alternatively activated microglia/macrophages; MDA, malondialdehyde; MPO, myeloperoxidase; SCI, spinal cord injury; SD, Sprague–Dawley; SE, status epilepticus; WT, wild type. SULFONES (DAPSONE AND SULFASALAZINE) Sulfones, particularly dapsone and sulfasalazine, have emerged as promising agents in the realm of neuroprotection within CNS. These compounds are traditionally recognized for their antimicrobial and anti‐inflammatory properties. They are now being investigated for therapeutic benefits in neurodegenerative diseases, SCI, and epilepsy. This section explores the neuroprotective mechanisms of sulfones, their clinical applications, and their implications for CNS disorders. Sulfones can influence apoptotic pathways, promoting the survival of neurons in conditions of stress. Dapsone has been shown to modulate the expression of pro‐apoptotic and anti‐apoptotic proteins, leading to reduced neuronal cell death and improved outcomes in models of CNS injury. 88 Research indicates that sulfones may activate neuroprotective signaling pathways, such as the nuclear factor erythroid 2‐related factor 2 (Nrf2) pathway, which plays a crucial role in cellular defense against oxidative stress. 89 By enhancing the expression of Nrf2 target genes, sulfones can promote cellular resilience and neuroprotection in the face of neurotoxic challenges. 90 , 91 Dapsone in spinal cord injury Recent studies highlight the potential of dapsone, an irreversible MPO inhibitor, in mitigating SCI‐induced damage. In animal models, dapsone has demonstrated significant neuroprotective effects, including decreased MPO activity, reduced lipid peroxidation, and enhanced motor function recovery. Additionally, dapsone treatment improved tissue sparing and decreased mortality, suggesting its role in protecting spinal cord integrity and promoting recovery post‐SCI. 92 Beyond its anti‐inflammatory effects, dapsone has been shown to exert anti‐apoptotic effects following SCI. In rat models, dapsone administration reduced the activity of caspases‐8, ‐9, and ‐3, which are critical mediators of apoptosis. This reduction in caspase activity was associated with fewer apoptotic cells, as evidenced by decreased Annexin V and TUNEL‐positive cells in the lesion area. These findings underscore dapsone's multifaceted protective roles in SCI, addressing both inflammatory and apoptotic pathways to improve recovery outcomes. 88 Furthermore, dapsone's anti‐nociceptive effects have been investigated in the context of neuropathic pain (NP) following SCI, a debilitating condition characterized by heightened pain sensitivity. Dapsone has shown promise in alleviating tactile allodynia and mechanical hyperalgesia in SCI models. The drug's antioxidant properties, including the reduction of lipid peroxidation and enhancement of glutathione levels, were central to its efficacy in mitigating pain. These results suggest that dapsone's ability to modulate oxidative stress and excitotoxicity may offer a novel approach to managing SCI‐induced NP. 93 In evaluating dapsone's therapeutic potential, studies have also examined its impact on the early and late phases of recovery following SCI. Acute‐phase treatment with dapsone has demonstrated dose‐dependent anti‐inflammatory effects, including reduced levels of GRO/KC, neutrophil infiltration, and macrophage presence in injured tissues. These early anti‐inflammatory effects were linked to improved motor function recovery, with sustained benefits observed 7 weeks post‐injury. These findings support the use of dapsone as a promising candidate for enhancing both immediate and long‐term functional recovery following SCI. 94 In another study, vincristine‐induced peripheral neuropathy (VIPN) was utilized in male Wistar rats through vincristine injections, and the effects of dapsone were assessed when administered 30 min before vincristine. The results showed that dapsone treatment significantly improved the thermal and mechanical sensitivity, which were diminished in VIPN, as well as enhanced motor neuron conduction velocity (MNCV). Dapsone also reduced markers of inflammation, oxidative stress, and apoptosis, such as TNF‐α, NF‐kB, malondialdehyde (MDA), and caspase‐3 activity, while it increased the antioxidant GSH levels in the sciatic nerve. Moreover, histopathological analysis showed that dapsone prevented the demyelination of the sciatic nerve induced by VCR. 95 Lastly, the potential of dapsone extends beyond neurodegenerative conditions to musculoskeletal disorders, such as osteoarthritis. In osteoarthritis models, dapsone has been shown to reduce pain, inflammation, and cartilage degradation, with significant improvements in mechanical allodynia and thermal hyperalgesia. Dapsone's ability to lower inflammatory markers like TNF‐α, IL‐1β, and NF‐κB, while protecting against cartilage damage, suggests its broader applicability in treating inflammatory joint diseases. These findings position dapsone as a versatile therapeutic agent with potential benefits for both SCI and osteoarthritis, offering a promising avenue for further clinical exploration. 96 Dapsone in neurodegenerative diseases Dapsone has been investigated for its role in reducing neuroinflammation associated with neurodegenerative diseases like Alzheimer's Disease (AD). A study focused on patients with leprosy, and AD examined dapsone's effect on the cGAS/STING signaling pathway, crucial for triggering innate immune responses that can worsen neurodegeneration. Findings revealed that dapsone treatment significantly lowered both the incidence and prevalence of AD, especially among patients diagnosed with the disease. Specifically, the treatment group (T1) had a reduced incidence of AD compared to the untreated group (T3), while higher prevalence rates were noted in groups that did not receive dapsone. This supports the drug's potential as a preventive therapy for slowing AD progression by targeting neuroinflammation. 97 Another study investigated the neuroprotective effects of dapsone in a scopolamine‐induced memory impairment model in mice, a common model for studying memory disorders. The research focused on dapsone's role in modulating nitric oxide (NO) pathways. The results demonstrated that dapsone improved memory acquisition at doses of 5 mg/kg, as measured by performance in the Y‐maze and passive‐avoidance tests. Furthermore, the neuroprotective effects of dapsone were reversed when specific inhibitors of nitric oxide synthase (NOS) were administered, suggesting that the nitrergic pathway is involved in dapsone's mechanism of action. These findings support the hypothesis that dapsone can improve memory functions and protect against neurodegeneration, potentially by modulating NO signaling pathways. 98 Dapsone in epilepsy Several studies have explored its effects across different animal models of epilepsy, highlighting its ability to suppress seizures and reduce neuronal damage. In a study involving amygdala and hippocampal kindling models of epilepsy, dapsone demonstrated dose‐dependent suppression of generalized seizures in rats, with effective doses (6.25–12.5 mg/kg) overlapping with those used clinically for leprosy treatment. 99 However, in cats, higher doses (13–23 mg/kg) were required, and neurotoxic signs were observed at therapeutic serum levels, emphasizing the need for careful dosing when considering long‐term use. 100 Further investigations into the effects of dapsone on kainic acid (KA)‐induced neurotoxicity revealed its antioxidative, anticonvulsive, and neuroprotective effects. Dapsone, either alone or in combination with phenobarbital, reduced oxidative stress markers such as lipid peroxidation and glutathione depletion, and protected against neuronal death in the hippocampal CA‐3 pyramidal cell layer. The combination of DDS and PB did not show additive effects, suggesting that the two drugs could be used separately for treating epilepsy or SE, but their combined use was not superior to individual treatments. 101 In addition to its antioxidative properties, dapsone's neuroprotective effects have been linked to its ability to modulate inflammatory pathways. In a lithium‐pilocarpine‐induced SE model, pre‐ and post‐treatment with dapsone significantly reduced seizure severity and mortality. This protective effect was associated with decreased levels of TNF‐α and NO metabolites in the hippocampus. Interestingly, the anticonvulsive effects of dapsone were reversed by the administration of nitric oxide synthase inhibitors, suggesting that the modulation of the nitrergic pathway plays a key role in its therapeutic action. 102 In the most recent study, the researchers used two seizure models, pentylenetetrazole‐induced clonic seizures and maximal electroshock‐induced generalized tonic‐clonic seizures (GTCS). Results showed that dapsone increased CST, decreased seizures, and prevented GTCS and mortality in the MES model. It also modulated Nrf2/HO‐1 and NLRP3 pathways. The findings suggest dapsone's potential in treating epilepsy, particularly in drug‐resistant cases. 103 Regarding stroke, dapsone prevents neuronal damage from glutamate agonists. In a model of permanent middle cerebral artery occlusion in rats, dapsone treatment significantly improved neurological deficits, reducing infarction volume by 93% and 92% compared to control values. 104 Additionally, 30 patients with ischemic stroke were included in a pilot clinical trial to evaluate the use of dapsone in treating cerebral infarction. Patients with a score of greater than four on the National Institute of Health Stroke Scale were randomly assigned to receive a single dose of 200 mg dapsone or a placebo. The results showed that patients who received treatment had favorable scores, with the best outcomes occurring when treatment began within the first 8 to 10 h after the stroke, and there were no reported adverse drug reactions. 105 A summary of neuroprotective effects of dapsone in preclinical studies has been indicated in Table 3. TABLE 3Neuroprotective effects of dapsone in preclinical models of spinal cord injury, stroke, and epilepsy.DiseaseDose and route of administrationAnimal modelMechanisms and outcome of treatmentLimitationsRef.Spinal Cord Injury12.5 mg/kg, for 3 daysAdult female Wistar rats in weight‐drop model MPO and Mortality ↓ Histopathology improvement ↑ Only adult female rats included. Only one dose evaluated. [92]12.5 mg/kg, for 3 daysAdult female Wistar rats in weight‐drop model Caspase‐8, 9, and 3 ↓ Annexin V and TUNEL‐positive cells ↓ Only adult female rats included. Only one dose evaluated. [88]3.1–25 mg/kg, i.p., acuteAdult female Wistar rats in weight‐drop model Neuropathic pain, lipid peroxidation, and NMDA ↓ GSH ↑ Only adult female rats included.[93]37.5 mg/kgAdult female Wistar rats in weight‐drop model Motor function recovery ↑ Macrophage ↓ Only adult female rats included[94]Stroke9.375 or 12.5 mg/kg 30 min after occlusionMale Wistar rats with MCA permanent occlusion Ischemic volume ↓ Neurological score ↑ Only male rats included.[104]12.5 mg/kgMale adult Wistar rats ROS, Nrf2 ↓ Fractional anisotropy ↑ Only male rats included.[106]12.5 mg/kg after 6 hMale adult Wistar ratsNeuronal damage ↓ via JNK, PTEN, Calpain, Caspase‐3 ↓Only male rats included.[107]Epilepsy2, 5, 10, and 20 mg/kg, ip, acuteAdult male mice Nrf2, HO‐1 ↑ NLRP3, IL‐1 β/IL‐18, and IL‐8 ↓ Only male mice included.[103]2, 5, 10, and 20 mg/kg, oralAdult male rats in Li‐pilocarpine SE model TNF‐α and NO ↓ Seizure score and mortality ↓ via nitrergic system Only male rats included.[102]13–23 mg/kg in cats; 6.25–12.5 mg/kg, i.p. in ratsAmygdaloid kindling model in catsLong‐term anticonvulsant effectsNo molecular assessments.[99] Note: All studies were conducted in animal models; no clinical data are included. ↑ increase; ↓ decrease.Abbreviations: GSH, glutathione; HO‐1, heme oxygenase‐1; i.p., intraperitoneal; JNK, c‐Jun N‐terminal kinase; MCA, middle cerebral artery; MPO, myeloperoxidase; NMDA, N‐methyl‐d‐aspartate; Nrf2, nuclear factor erythroid 2–related factor 2; PTEN, phosphatase and tensin homolog; ROS, reactive oxygen species; SCI, spinal cord injury; SE, status epilepticus. Neuroprotective effects of dapsone in preclinical models of spinal cord injury, stroke, and epilepsy. MPO and Mortality ↓ Histopathology improvement ↑ Only adult female rats included. Only one dose evaluated. Caspase‐8, 9, and 3 ↓ Annexin V and TUNEL‐positive cells ↓ Only adult female rats included. Only one dose evaluated. Neuropathic pain, lipid peroxidation, and NMDA ↓ GSH ↑ Motor function recovery ↑ Macrophage ↓ Ischemic volume ↓ Neurological score ↑ ROS, Nrf2 ↓ Fractional anisotropy ↑ Nrf2, HO‐1 ↑ NLRP3, IL‐1 β/IL‐18, and IL‐8 ↓ TNF‐α and NO ↓ Seizure score and mortality ↓ via nitrergic system Note: All studies were conducted in animal models; no clinical data are included. ↑ increase; ↓ decrease. Abbreviations: GSH, glutathione; HO‐1, heme oxygenase‐1; i.p., intraperitoneal; JNK, c‐Jun N‐terminal kinase; MCA, middle cerebral artery; MPO, myeloperoxidase; NMDA, N‐methyl‐d‐aspartate; Nrf2, nuclear factor erythroid 2–related factor 2; PTEN, phosphatase and tensin homolog; ROS, reactive oxygen species; SCI, spinal cord injury; SE, status epilepticus. ANTIPARASITIC (IVERMECTIN AND NICLOSAMIDE) Ivermectin, known for its antiparasitic properties, targets glutamate‐gated chloride channels in parasites organisms. It also modulates mammalian targets like Farnesoid X receptor (FXR) and Glycine receptor α1 subunit (GlyRα1), potentially influencing inflammatory signaling pathways. The P2X (4) receptor is part of the purinergic ionotropic receptor family and plays a crucial role in various neurological and behavioral functions, including pain, hippocampal plasticity, and neuroendocrine regulation. 108 Ivermectin, a potent positive allosteric modulator of P2X4, has been tested for its effects on multiple aspects of behavior in mice. In behavioral paradigms, ivermectin (2.5–10 mg/kg, i.p.) produced significant anxiolytic‐like effects in the elevated plus maze and marble burying tests. It also induced depression‐like behavior in tail‐suspension and forced swim tests. Interestingly, ivermectin did not affect locomotor activity in the open field test but increased time spent in the peripheral zone. Additionally, the drug impaired sensorimotor gating as indicated by a dose‐dependent reduction in pre‐pulse inhibition of the acoustic startle reflex. These behavioral effects were absent or significantly altered in P2X4 knockout mice, suggesting that P2X4 receptors are involved in the modulation of certain behaviors, particularly sensorimotor gating. However, some effects, such as those in the open field and elevated plus maze, were similar between wild‐type and knockout mice, implying that additional mechanisms may also contribute to ivermectin actions. These findings underscore the complex role of P2X4 receptors in behavioral regulation and the potential for ivermectin in influencing these processes, though further research is needed to fully understand the mechanisms involved. 109 Ivermectin in epilepsy Ivermectin has been shown to enhance GABA receptor signaling, which plays a crucial role in inhibitory neurotransmission. By potentiating GABAergic activity, ivermectin may help to stabilize neuronal excitability and reduce the likelihood of seizures, making it a potential adjunctive treatment for epilepsy. This mechanism can help balance excitatory and inhibitory signaling in the brain, crucial for managing seizure disorders. Ivermectin has shown promising anticonvulsant properties, though its exact mechanisms remain under investigation. Several studies have demonstrated its potential in modulating seizure thresholds in various animal models. In the PTZ‐induced clonic seizure model, ivermectin at doses of 0.5 to 10 mg/kg increased the clonic seizure threshold (CST), providing significant protection against seizures. This anticonvulsant effect was enhanced by low doses of the GABAA receptor positive allosteric modulator diazepam and the ATP‐sensitive potassium (KATP) channel opener cromakalim. In contrast, the effects were inhibited by the GABAA receptor antagonist flumazenil and the KATP channel blocker glibenclamide. These findings suggest that ivermectin anti‐seizure activity is mediated by the modulation of GABAA receptors and KATP channels. 110 Further investigation into ivermectin pharmacological mechanisms also highlights the involvement of opioidergic and nitrergic systems in its anticonvulsant effects. Studies using the PTZ model indicated that co‐administration of opioid receptor agonists (such as morphine) and nitric oxide inhibitors (like l‐NAME and 7‐NI) significantly enhanced ivermectin anticonvulsant action. This interaction suggests that ivermectin seizure‐suppressing effects may involve the modulation of the opioidergic system and the nitric oxide pathway. These findings emphasize the multifactorial nature of ivermectin anticonvulsant properties. 111 In a model of SE induced by lithium‐pilocarpine, ivermectin demonstrated a dose‐dependent reduction in seizure severity and a decrease in pro‐inflammatory cytokines, such as TNF‐α and IL‐1β, in the hippocampus. The drug also increased the expression of GABAA receptors, which may further contribute to its neuroprotective effects. The enhancement of ivermectin anticonvulsant action by diazepam, nicorandil, and morphine, along with the reversal of its effects by glibenclamide and naltrexone, underscores the involvement of GABAA receptors, KATP channels, and the opioidergic system in mediating its effects. 112 Ivermectin, has been shown to have anticonvulsant properties in onchocerciasis‐associated epilepsy (OAE) due to its association with Onchocerca volvulus infection. Clinical and modeling studies have shown that ivermectin reduces microfilarial load and may impact seizure incidence and severity. 113 Studies in Cameroon and Tanzania have linked microfilarial burden in children to epilepsy development, suggesting that biannual mass drug administration could eliminate OAE in hyperendemic regions. A follow‐up study in Tanzania confirmed a significant reduction in microfilarial density three months post‐ivermectin treatment, highlighting the need for optimization in persistent transmission zones. 114 A randomized clinical trial in the Democratic Republic of Congo found no significant difference in seizure reduction over time compared to phenobarbital alone, highlighting the need for larger, well‐controlled studies. 115 These studies suggest ivermectin has a dual role in OAE: as a preventive agent via vector control and as a possible adjunct therapeutic through anti‐inflammatory and GABAergic mechanisms. However, definitive evidence from large‐scale randomized controlled trials is still needed to solidify its role in epilepsy management in endemic areas. 116 Neuroprotective effects of niclosamide Niclosamide, an anthelmintic drug, has demonstrated efficacy in suppressing pruritus through its interaction with metabotropic glutamate receptors (mGluRs). Pruritus, often driven by serotonin and other pruritogens, can lead to discomfort that antihistamines, which target histamine pathways, may not alleviate. In a study using mouse models of serotonergic itch, treatment with 5 mg/kg Niclosamide led to significant suppression of pruritus and a reduction in the expression of mGluR1, mGluR5, 5‐HT2 receptors, and TRPV1. These findings suggest niclosamide's potential as an antipruritic agent, likely acting through modulation of glutamatergic and serotonergic signaling pathways. 117 Niclosamide, along with quinacrine, has been shown to increase neurite length in dopaminergic neurons and protect against neurotoxins (MPP+ and 6‐OHDA). This effect is mediated through activation of the BMP‐Smad signaling pathway, suggesting niclosamide's potential as a neuroprotective therapy in PD. Given its FDA approval for other uses, Niclosamide is a promising candidate for further studies in PD treatment. 118 In ALS, a neurodegenerative disease marked by motor neuron loss, existing treatments are limited, underscoring the need for novel therapeutic approaches. Niclosamide, known for its anti‐inflammatory and anti‐fibrotic properties, has shown promise in ALS models. In both SOD1‐G93A and FUS transgenic mice, Niclosamide administration slowed disease progression, improved survival, and alleviated symptoms such as gliosis, motor neuron loss, and muscle atrophy. The drug's multi‐targeted effects, including the inhibition of STAT3 and mTOR pathways, position Niclosamide as a strong candidate for repurposing in ALS therapy. 119 In an animal model of autism spectrum disorder (ASD), Niclosamide exhibited significant neuroprotective effects. Administration of Niclosamide (50 and 100 mg/kg) restored behavioral and biochemical impairments in rats with an autism‐like phenotype induced by PPA infusion. The treatment also affected molecular markers associated with oxidative stress and neuroinflammation, notably decreasing cytokines like TNF‐α, IL‐6, and IFN‐γ. The ERK/MAPK signaling pathway, particularly the activation of Nrf2 and ERK2, was implicated in these effects, indicating that niclosamide may be a potential therapeutic candidate for ASD 120 (see Table 4). TABLE 4Neuroprotective effects of ivermectin in preclinical models of stroke and epilepsy.DiseaseDose and route of administrationAnimal ModelMechanisms and outcome of treatmentLimitationsRef.Stroke2 mg/kg/day, ipMale Wistar rats with transient global IR via bilateral carotid artery occlusion MPO, MDA, brain infarct size ↓ AMPA ↑ Memory and neuroprotection ↑ Only male rats included[121]Epilepsy5, 10, and 15 mg/kg, i.p.Male ICR miceSeizure activity and death ↓ Only male mice included No molecular assessments [122]0.2 to 5 mg/kg, i.p., acute pre‐treatmentMale adult miceCST ↑ via nitrergic and opioidergic systemsOnly male mice included[111]0.1 to 10 mg/kg, i.p., acute pre‐treatmentMale adult miceCST ↑ via GABAA receptor and KATP channelsOnly male mice included[110]0.2 to 5 mg/kg, i.p. pre‐treatmentMale adult ratsSeizure severity ↓ via neuroinflammation modulationOnly male rats included[112] Note: All studies were conducted in animal models; no clinical data are included. ↑ increase; ↓ decrease.Abbreviations: AMPA, α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor; CST, current seizure threshold; GABA_A, γ‐aminobutyric acid type A receptor; i.p., intraperitoneal; IR, ischemia–reperfusion; KATP, ATP‐sensitive potassium channels; MDA, malondialdehyde; MPO, myeloperoxidase. Neuroprotective effects of ivermectin in preclinical models of stroke and epilepsy. MPO, MDA, brain infarct size ↓ AMPA ↑ Memory and neuroprotection ↑ Only male mice included No molecular assessments Note: All studies were conducted in animal models; no clinical data are included. ↑ increase; ↓ decrease. Abbreviations: AMPA, α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor; CST, current seizure threshold; GABA_A, γ‐aminobutyric acid type A receptor; i.p., intraperitoneal; IR, ischemia–reperfusion; KATP, ATP‐sensitive potassium channels; MDA, malondialdehyde; MPO, myeloperoxidase. ANTI‐MALARIA (CHLOROQUINE AND HYDROXYCHLOROQUINE) Chloroquine and hydroxychloroquine (HCQ), primarily known for their use in treating malaria and autoimmune diseases like rheumatoid arthritis and lupus, have garnered attention for their potential neuroprotective effects in CNS. Both chloroquine and hydroxychloroquine are well‐known autophagy inhibitors. Autophagy is a critical cellular process that helps remove damaged proteins and organelles, thereby maintaining cellular homeostasis. In neurodegenerative diseases, dysregulated autophagy can lead to the accumulation of toxic proteins and contribute to neuronal death. 123 Chloroquine in spinal cord injury One study found that Chloroquine treatment significantly enhanced locomotor function in rats after SCI. It inhibited autophagy‐related inflammation by preventing the degradation of I‐κBα, crucial for regulating the NF‐κB pathway, thereby reducing inflammatory cytokines. Chloroquine also alleviated endoplasmic reticulum (ER) stress via the ATF4 pathway, essential for ER‐stress‐induced autophagy. Experiments showed that overexpression of p62 intensified I‐κBα degradation and inflammation, while Chloroquine mitigated these impacts, highlighting its protective role. 124 Chloroquine demonstrates neuroprotective effects in a rat model of traumatic brain injury (TBI) by reducing cerebral edema, improving motor and cognitive functions, and suppressing inflammation. It inhibits neuronal autophagy, as shown by decreased LC3 expression, and lowers pro‐inflammatory cytokines like IL‐1β and TNF‐α in the hippocampus. These findings suggest Chloroquine may attenuate TBI‐induced damage through its anti‐autophagic and anti‐inflammatory actions. 125 Chloroquine in epilepsy Chloroquine significantly affects seizure activity in epilepsy by modulating dopaminergic, noradrenergic, opioidergic, and nitrergic systems. Dopaminergic agents, such as apomorphine and l‐dopa, increase seizure incidence and decrease latency in Chloroquine‐induced seizures. In contrast, alpha‐methyl‐p‐tyrosine inhibits this effect by reducing dopamine synthesis, thereby extending latency and lowering seizure incidence. Additionally, dopaminergic antagonists like haloperidol and pimozide provide protective effects against these seizures, which can be reversed by pro‐dopaminergic agents, indicating the complexities of neurotransmitter modulation in this context. 126 In clinical settings, an investigation into the relationship between Chloroquine blood levels and seizure activity in children with cerebral malaria revealed a complex association. While baseline Chloroquine concentrations were not directly correlated with seizure occurrence, children experiencing status epilepticus had significantly lower Chloroquine levels. These findings suggest that subtherapeutic Chloroquine levels may contribute to increased seizure susceptibility in vulnerable populations. 127 Preclinical studies emphasize the involvement of opioidergic and nitrergic systems in Chloroquine's anticonvulsant effects. At low doses (5 mg/kg), Chloroquine enhances seizure thresholds, mediated through increased hippocampal nitrite levels and opioid receptor activation. This effect is reversed by opioid antagonist naltrexone and NOS inhibitors like l‐NAME and 7‐NI, highlighting the synergistic interaction between opioidergic and nitric oxide signaling pathways. However, at higher doses (20 mg/kg), Chloroquine paradoxically reduces seizure thresholds, indicating dose‐dependent effects. 128 A comparison of Chloroquine and mefloquine reveals overlapping mechanisms of action in seizure modulation. Both drugs enhance seizure thresholds and reduce seizure frequency and mortality in PTZ‐ and MES‐induced seizure models. Their anticonvulsant effects are reversed by pre‐treatment with opioid and NOS inhibitors, supporting shared reliance on opioidergic and nitrergic pathways. Morphine co‐administration further potentiates these effects, reinforcing the role of opioid receptors in seizure protection. 129 Taken together, Chloroquine exhibits dualistic, dose‐dependent effects on seizure activity, mediated by its intricate interplay with dopaminergic, opioidergic, and nitrergic systems. Its low‐dose anticonvulsant properties, particularly through nitric oxide and opioid signaling pathways, offer promising insights for neuroprotection in epilepsy. However, the proconvulsive tendencies at higher doses necessitate careful dosing strategies. Future studies are warranted to refine chloroquine's therapeutic potential and elucidate its mechanisms in epilepsy and related disorders. Chloroquine in stroke Chloroquine exhibits significant neuroprotective and anti‐inflammatory properties in experimental stroke models, targeting multiple mechanisms to reduce cerebral damage and enhance recovery. In a tGCI rat model, Chloroquine pretreatment (60 mg/kg, 2 h before ischemia) mitigated post‐stroke learning and memory deficits. It achieved this by attenuating the expression of key inflammatory mediators, including TLR3, interferon regulatory factor 3 (IRF3), and interferon‐β (IFN‐β), in the hippocampus. This suggests that Chloroquine's neuroprotective effects involve suppression of the TLR3/IRF3‐IFN‐β signaling pathway, which is crucial for stroke‐induced inflammation. 130 In ischemic stroke models induced by MCAO, Chloroquine was administered to both diabetic (ob/ob) and WT mice over 3 weeks before stroke induction. In diabetic mice, Chloroquine normalized blood glucose levels, a critical factor for reducing stroke severity in high‐risk patients. Across all mice, Chloroquine reduced cerebral damage, lowered inflammatory markers like HMGB1 in cerebrospinal fluid and serum, and decreased MPO activity and inflammatory cytokine expression. Additionally, Chloroquine attenuated harmful DNA damage signaling by suppressing PARP and p53 activation, highlighting its role in protecting neuronal integrity. 131 Chloroquine reduces cerebral injury and improves functional outcomes in stroke by modulating inflammation, restoring glucose homeostasis, and protecting against DNA damage. It shows promise as a therapeutic agent for stroke prevention, particularly in diabetic patients. In a PD model, Chloroquine stabilized dopamine levels, preserved dopaminergic neurons, and reduced behavioral and cognitive deficits. It inhibited abnormal autophagy, decreased cerebral inflammation by lowering pro‐inflammatory cytokines, and demonstrated antioxidant effects by reducing reactive oxygen species and promoting neuro‐restoration. 132 Summary of these findings is written in Table 5 and Figure 1. TABLE 5Neuroprotective effects of chloroquine in preclinical models of neurological disorders.DiseaseDose and route of administrationAnimal modelMechanisms and outcome of treatmentLimitationsRef.Spinal Cord Injury50 mg/kg/day, for one weekYoung adult female SD rats locomotor activity (Basso–Beattie–Bresnahan score) ↑ Histopathological score ↑ M1 macrophage genes ↓ M2 macrophage genes ↑ Autophagy and I‐kBα degradation ↓ Only female rats included Only one dose evaluated[124]Stroke45 mg/kg i.p.Three‐month‐old male Wistar rats with Aβ injection Ganglioside homeostasis ↑ Pathological and functional performance ↑ Only male rats included Only one dose evaluated [133]3 mg/kg after injurySD ratsLC3 and inflammatory cytokines ↓Sex was not determined[125]Epilepsy5 mg/kg, i.p., acute (hormetic effects)Adult male mice Tonic hindlimb extension ↓ CST ↑ via opioidergic and nitrergic systems Only male mice included[128, 129]1–5 mg/kg, i.p. (biphasic effects)Male Swiss miceclonic convulsions ↓Only male mice included[134]Parkinson's disease8 mg/kg, i.p. after injuryMale BALB/c mice IL‐1β, TNF‐α, ROS ↓ LC3B & Beclin1 ↓ as autophagy markers Only male mice included[132]Alzheimer's disease50 mg/kg, for two monthsMale adult Wistarrats Autophagic process ↑ Myopathic induction in skeletal muscle Only male rats included[135]45 mg/kg for 6 daysBoth male and female wild type and transgenic mice BBB integrity ↑ excitotoxic processes and the vascular dysfunction ↓ Only one dose selected[136]Multiple sclerosis5 mg/kgBoth male and female C57BL/6 and B6SJLF1 miceLeukocytes modulation ↑ (oligodendrocytes, microglia, and astrocytes)Only one dose selected[137] Note: All studies were conducted in animal models; no clinical data are included. ↑ increase; ↓ decrease.Abbreviations: Aβ, amyloid‐β; blood–brain barrie; CST, current seizure threshold; IL‐1β, interleukin‐1 beta; i.p., intraperitoneal; LC3/LC3B, microtubule‐associated protein 1 light chain 3; I‐κBα, inhibitor of nuclear factor kappa B alpha; ROS, reactive oxygen speciesr; TNF‐α, tumor necrosis factor‐alpha. Neuroprotective effects of chloroquine in preclinical models of neurological disorders. locomotor activity (Basso–Beattie–Bresnahan score) ↑ Histopathological score ↑ M1 macrophage genes ↓ M2 macrophage genes ↑ Autophagy and I‐kBα degradation ↓ Ganglioside homeostasis ↑ Pathological and functional performance ↑ Only male rats included Only one dose evaluated Tonic hindlimb extension ↓ CST ↑ via opioidergic and nitrergic systems IL‐1β, TNF‐α, ROS ↓ LC3B & Beclin1 ↓ as autophagy markers Autophagic process ↑ Myopathic induction in skeletal muscle BBB integrity ↑ excitotoxic processes and the vascular dysfunction ↓ Note: All studies were conducted in animal models; no clinical data are included. ↑ increase; ↓ decrease. Abbreviations: Aβ, amyloid‐β; blood–brain barrie; CST, current seizure threshold; IL‐1β, interleukin‐1 beta; i.p., intraperitoneal; LC3/LC3B, microtubule‐associated protein 1 light chain 3; I‐κBα, inhibitor of nuclear factor kappa B alpha; ROS, reactive oxygen speciesr; TNF‐α, tumor necrosis factor‐alpha. Neuroprotective pathways influenced by antimicrobial agents. Antimicrobials such as minocycline, azithromycin, dapsone, chloroquine, and ivermectin act on multiple interconnected mechanisms. They attenuate neuroinflammation by suppressing microglial activation and reducing pro‐inflammatory cytokines (e.g., TNF‐α, IL‐1β, IL‐6), inhibit oxidative stress through antioxidant and mitochondrial‐stabilizing effects, and modulate autophagy to restore cellular homeostasis. Additional actions include regulation of NF‐κB and MAPK signaling, preservation of blood–brain barrier integrity, and modulation of the gut–brain axis via microbiota and immune signaling. CASPASE, Cysteine‐aspartic proteases (enzymes involved in apoptosis); COX, Cyclooxygenase; GABAA, Gamma‐aminobutyric acid type A receptor; IL‐1β, Interleukin‐1 beta; MAPK, Mitogen‐activated protein kinase; MPO, Myeloperoxidase; NO, Nitric oxide; TNF‐α, Tumor necrosis factor‐alpha. Symbol: → Horizontal arrow indicating activation, progression, or signaling. Brain schematic represents the central nervous system. THE GUT‐BRAIN AXIS IN NEUROPROTECTIVE EFFECTS OF ANTIMICROBIAL AGENTS The gut‐brain axis (GBA) represents a dynamic, bidirectional signaling network integrating CNS, enteric nervous system, immune system, endocrine signaling, and intestinal microbiota. Increasing evidence indicates that the gut microbiome exerts a profound influence on CNS function through modulation of neuroinflammation, synaptic plasticity, 138 neurotransmitter biosynthesis, and BBB integrity. 139 In this context, antimicrobial agents have garnered attention for their ability to modulate the GBA and thereby confer neuroprotection via indirect, microbiota‐mediated pathways. From a pharmacological standpoint, antimicrobial‐induced microbiome remodeling can alter the production and systemic availability of key microbial metabolites such as short‐chain fatty acids (SCFAs), 140 indole derivatives, γ‐aminobutyric acid (GABA), serotonin precursors, 141 and lipopolysaccharides (LPS). 142 These metabolites act on both peripheral immune cells and CNS‐resident glia, modulating inflammatory tone and neural excitability. For instance, butyrate and propionate, produced by anaerobic gut bacteria, are known histone deacetylase (HDAC) inhibitors that enhance neurotrophic signaling (e.g., BDNF expression) and suppress NF‐κB‐mediated neuroinflammation. 143 Antibiotics that selectively enhance the abundance of SCFA‐producing taxa may therefore confer epigenetic and anti‐inflammatory neuroprotection. Minocycline is a paradigmatic example of an antibiotic with robust neuroprotective activity that may be partially mediated by GBA modulation. Recent preclinical work highlights how antimicrobial agents modulate GBA to influence neuroinflammation, neurotransmission, and BBB integrity in mood disorders. In a well‐characterized model of major depressive disorder using high‐anxiety‐like behavior (HAB) rats, minocycline treatment not only alleviated depressive‐like behavior but also reduced circulating pro‐inflammatory cytokines and altered microglial density in the prefrontal cortex in a sex‐ and trait‐dependent manner. Importantly, these central effects were paralleled by robust remodeling of the gut microbiota: minocycline increased the relative abundance of Lachnospiraceae and Clostridiales Family XIII, both of which are major butyrate‐producing taxa. The study found that minocycline's neuroprotective and antidepressant effects are not limited to direct microglial inhibition but also mediated through microbiota‐derived metabolites, modulating immune tone, neurotransmitter synthesis, and barrier function. This suggests the microbiome–gut–brain axis as a potential therapeutic target for antimicrobial repurposing in depression. 144 Rifaximin, a poorly absorbed rifamycin derivative, exemplifies how locally acting antimicrobials can exert CNS effects via the GBA. In patients with hepatic encephalopathy, rifaximin restores gut barrier function, reduces bacterial translocation, and lowers systemic pro‐inflammatory cytokines (e.g., IL‐6, TNF‐α), leading to improved neurocognitive outcomes. 145 In preclinical neurodegeneration models, rifaximin enhances the expression of tight junction proteins (e.g., occludin, claudin‐5) and reduces glial reactivity, effects that are microbiota‐dependent. 146 Furthermore, antiparasitic agents such as ivermectin have shown the capacity to modulate the gut microbiome and downstream immune signaling. The effects of antimicrobial agents on GBA and their neuroprotective roles are summarized in Table 6. TABLE 6Neuroprotective effects of minocycline and rifaximin mediated through the gut–brain axis (GBA).Antimicrobial agentMicrobiota/GBA effectNeurological relevanceRef.MinocyclineGut dysbiosis following SCI ↓ Anxiety‐like behavior ↓ long‐term effects on cytokines and chemokines after SCI [21]Gut microbiota composition improvement ↑ Overall gut bacterial load and diversity ↓ but selectively ↑ Clostridiales families (Lachnospiraceae and Family XIII); therefore ↑ plasma 3‐OH‐butyrate levels Depressive‐like phenotype ↓ Microglial density ↓ [144]RifaximinContent of butyrate in the brain ↑ Depressive‐like behavior ↓ Cognitive impairment ↓ [147] Note: All studies were conducted in animal models; no clinical data are included. ↑ increase; ↓ decrease.Abbreviations: GBA, gut–brain axis; MMP, matrix metalloproteinase; SCI, spinal cord injury; 3‐OH‐butyrate, 3‐hydroxybutyrate. Neuroprotective effects of minocycline and rifaximin mediated through the gut–brain axis (GBA). Anxiety‐like behavior ↓ long‐term effects on cytokines and chemokines after SCI Depressive‐like phenotype ↓ Microglial density ↓ Depressive‐like behavior ↓ Cognitive impairment ↓ Note: All studies were conducted in animal models; no clinical data are included. ↑ increase; ↓ decrease. Abbreviations: GBA, gut–brain axis; MMP, matrix metalloproteinase; SCI, spinal cord injury; 3‐OH‐butyrate, 3‐hydroxybutyrate. CONCLUSION AND CHALLENGES IN ANTIBIOTIC REPURPOSING The repurposing of antibiotics as therapeutic agents for non‐infectious diseases, including neurological disorders, represents a transformative shift in modern pharmacology. This strategy leverages the well‐characterized pharmacokinetics, safety profiles, and accessibility of existing antimicrobial agents to address unmet clinical needs. However, the journey from bench to bedside involves significant scientific, regulatory, and logistical challenges. This conclusion synthesizes the past and current progress, future directions, and obstacles in antibiotic repurposing, with a focus on neuroprotection and beyond. Preclinical evidence supporting antibiotic repurposing is subject to bias and methodological limitations. Many studies rely heavily on male rodents, neglecting known sex differences in neuroinflammatory responses and drug metabolism. Additionally, species‐specific pharmacodynamics and pharmacokinetics may limit the translational validity of animal models. Publication bias remains a significant concern, as negative or neutral findings (e.g., minocycline's failure in ALS trials) are less likely to be published, creating an overoptimistic impression of efficacy. Lack of standardized outcome measures across studies hinders meta‐analysis and reproducibility. Antimicrobial agents, traditionally essential for treating infections, are showing broader therapeutic potential beyond their original use. Research has highlighted their neuroprotective effects in conditions like neurodegenerative diseases and brain injuries, emphasizing their ability to influence inflammation, oxidative stress, and apoptosis. Repurposing these antibiotics can streamline drug development, lower costs, and leverage established safety profiles, making them accessible for off‐label use, especially in resource‐limited settings. 1 , 148 However, challenges persist. A key concern is the development of antibiotic resistance when these drugs are employed for non‐infectious indications. While the doses used in neuroprotection or inflammation are typically lower than those for infections, the risk of resistance and potential cross‐resistance with therapeutic antibiotics warrants careful consideration. Additionally, the long‐term off‐target effects, such as microbiome dysregulation, hepatotoxicity, or drug‐drug interactions, remain underexplored and necessitate comprehensive safety evaluations. 149 To address risks associated with antibiotic use in clinical settings, several strategies are recommended: employing non‐antibiotic derivatives with neuroprotective properties, using targeted drug delivery systems to limit systemic exposure, applying strict patient selection criteria, and conducting routine surveillance for resistance markers. Regulatory oversight is vital for enforcing careful prescription practices, especially in off‐label antibiotic use, to minimize unnecessary exposure. While minocycline has demonstrated neuroprotective effects in preclinical and early‐stage trials, results have varied in clinical settings. A phase III trial for ALS reported negative outcomes, contrasting with its positive results in SCI models. This discrepancy may stem from factors such as differing disease mechanisms, timing of administration (prophylactic vs. delayed), treatment duration, and dosage. Notably, high doses of minocycline in ALS were linked to quicker functional decline and adverse events, indicating that its safety and efficacy can be highly context‐dependent. In contrast, lower doses or nanoparticle‐based delivery systems have yielded benefits in traumatic or ischemic injury models, underscoring the necessity of model‐specific approaches, dose optimization, and timely administration in assessing repurposed antibiotics. Innovative targeted delivery methods, such as minocycline‐loaded nanoparticles, have shown potential in enhancing efficacy and reducing side effects, suggesting a way to improve systemic treatment limitations. 20 Repurposing faces additional regulatory complexity, especially when drugs approved for infectious diseases are repositioned for chronic, non‐infectious conditions. Regulatory pathways may require: New indications filed under the 505(b)(2) route (U.S.) or hybrid applications (EU), supported by robust preclinical and safety bridging data. Pharmacovigilance for off‐label use, especially in vulnerable populations (e.g., elderly, patients with comorbidities). Post‐marketing surveillance systems to monitor resistance development, adverse effects, and off‐target organ toxicity. Ongoing clinical research continues to probe the translational value of antimicrobial repurposing in neurology. Future avenues include precision medicine tailored to individual patient factors and the creation of non‐antibiotic derivatives alongside nanotechnology‐based delivery systems to enhance efficacy and reduce resistance. Additionally, integrating antimicrobial agents into combination therapies that address inflammation, oxidative stress, and synaptic dysfunction may define the future of neuroprotective strategies. Taken together, repurposing antibiotics combines science, innovation, and need. While early research results are hopeful, using these findings in regular medical treatment faces big challenges. Future studies should focus on making sure the treatments are safe, effective, and help reduce antibiotic resistance. Solving these problems can make repurposing antibiotics a potentially useful way to create affordable, cost‐effective, and innovative treatments for complex disorders. AUTHOR CONTRIBUTIONS Mohammad Amin Manavi: Software (equal); visualization (lead); writing—original draft (lead). Mohammadreza Salehi: Writing—review and editing (equal). Razieh Mohammad Jafari: Data curation (equal); validation (equal); visualization (equal); writing—review and editing (equal). Ramin Goudarzi: Data curation (equal); writing—review and editing (equal). Saman Khosravi: Writing—review and editing (equal). Ahmad Reza Dehpour: Conceptualization (lead); project administration (lead). CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. ETHICS STATEMENT This article is a review of previously published preclinical studies. No new human or animal subjects were directly involved, and no original ethical approval or informed consent was required for this synthesis. ACKNOWLEDGMENTS This manuscript has not been funded by any funding agencies in the public, commercial, or not‐for‐profit sectors. However, we would like to express our sincere gratitude to Alireza Mani, MD, PhD, for his invaluable assistance in providing English grammar checks and certification services. Throughout our collaboration, Dr. Mani's expertise and attention to detail significantly enhanced the quality and accuracy of our work. Manavi MA, Salehi M, Mohammad Jafari R, Goudarzi R, Khosravi S, Dehpour AR. Repurposing antimicrobial agents for neuroprotection: Mechanisms, clinical potential, and challenges. Neuroprotection. 2026;1‐25. 10.1002/nep3.70042 42023270 Managing Editor: Ningning Wang DATA AVAILABILITY STATEMENT Data available on request from the authors. No new data were generated or analyzed in this study. This review is based on previously published studies, which are cited in the manuscript. All relevant data can be accessed from these sources. REFERENCES Associated Data Data Availability Statement Data available on request from the authors. No new data were generated or analyzed in this study. This review is based on previously published studies, which are cited in the manuscript. All relevant data can be accessed from these sources.